TRML vs. IDYA, MESO, AGIO, APGE, AMPH, TARS, IOVA, IRON, IBRX, and WVE
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include IDEAYA Biosciences (IDYA), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Tourmaline Bio vs.
Tourmaline Bio (NASDAQ:TRML) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
IDEAYA Biosciences' return on equity of -19.42% beat Tourmaline Bio's return on equity.
Tourmaline Bio currently has a consensus target price of $54.00, suggesting a potential upside of 200.00%. IDEAYA Biosciences has a consensus target price of $53.67, suggesting a potential upside of 141.96%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.
Tourmaline Bio has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, IDEAYA Biosciences had 6 more articles in the media than Tourmaline Bio. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 2 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.87 beat IDEAYA Biosciences' score of -0.03 indicating that Tourmaline Bio is being referred to more favorably in the media.
IDEAYA Biosciences received 124 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 71.57% of users gave IDEAYA Biosciences an outperform vote.
Tourmaline Bio has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Summary
IDEAYA Biosciences beats Tourmaline Bio on 9 of the 17 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TRML) was last updated on 1/20/2025 by MarketBeat.com Staff
Free TRML Stock Alerts